Therapy Areas: Oncology
BeOne Medicines and Revolution Medicines expand oncology collaboration
10 August 2026 - BeOne Medicines Ltd (Nasdaq: ONC) (HKEX: 06160;) (SSE: 688235) and Revolution Medicines Inc (Nasdaq: RVMD) announced on Monday that the two oncology companies have entered a multi-par...
ValiRx receives notice of intention to grant Cytolytix European patent
10 August 2026 - Life science company ValiRx plc (AIM: VAL) reported on Monday that its majority-owned subsidiary Cytolytix Limited has received formal notification from the European Patent Office of ...
Akeso Advances reports first patient dosed in AK146D1 combined with ivonescimab breast cancer study
10 August 2026 - Chinese biopharmaceutical company Akeso Inc (HK:9926) announced on Monday that the first patient has been dosed in a Phase II clinical study evaluating AK146D1, its internally develop...
BioInvent receives FDA Fast Track designation for BI-1808 in ovarian cancer
7 August 2026 - Swedish biotech company BioInvent International AB (STO:BINV) announced on Friday that the US Food and Drug Administration (FDA) has granted Fast Track designation to its first-in-clas...
Northwest Biotherapeutics signs MOU for collaboration with SPIMACO in Saudi Arabia
7 August 2026 - Northwest Biotherapeutics (NWBio) (OTCQB:NWBO), a biotechnology company developing DCVax personalised immune therapies for solid tumour cancers, announced on Thursday that it has enter...
Innovent doses first colorectal cancer patient with IBI363/TAK-928 in combination with bevacizumab
6 August 2026 - China-based biopharmaceutical company Innovent Biologics Inc (HKEX: 01801) announced on Wednesday that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&a...